Thomas Beetham News Today

- THRIVE and THRIVE-2 clinical trials are continuing to enroll active and chronic thyroid eye disease (TED) patients; expected delivery of topline clinical results for both clinical trials on track for 2024 -- Timing for the selection of lead subcutaneous TED program is on track for the end of 2023 -- Advancing rece...

– Stephen Mahoney appointed President and Chief Executive Officer – – Potential best-in-class subcutaneous and intravenous thyroid eye disease programs targeting insulin-like growth factor 1...